Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival

Lupus

Volumn 17, Issue 4, 2008, Pages 281-288

  Siso A ^a,b   Ramos Casals, Manuel ^a,d   Bove A ^a   Brito Zeron P ^a   Soria, N ^a   Munoz S ^a   Testi, A ^a   Plaza, J ^a   Sentis J ^c   Coca, A ^d  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b GESCLINIC   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

Antimalarials; Cardiovascular disease; Hydroxychloroquine; Lupus nephropathy; Mortality; Systemic lupus erythematosus; Thrombosis

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INFECTION; KIDNEY BIOPSY; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ADOLESCENT; ADULT; AGED; ANTIMALARIALS; BIOPSY; CHILD; CHLOROQUINE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYCHLOROQUINE; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN;

EID: 43249098602     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307086503     Document Type: Article

References (35)

1. D'Cruz, DP, Khamashta, MA, Hughes, GR. Systemic lupus erythematosus. Lancet 2007; 369: 587-596.
2. Mok, CC, Ying, KY, Ng, WL, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006; 119: 355.e25-e33.
3. Huong, DL, Papo, T, Beaufils, H, et al. Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine (Baltimore) 1999; 78: 148-166.
4. Petri, M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996; 1: S16-S22.
5. Fessler, BJ, Alarcon, GS, McGwin, G, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005; 52: 1473-1480.
6. Ruiz-Irastorza, G, Egurbide, MV, Pijoan, JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006; 15: 577-583.
7. Tan, EM, Cohen, AS, Fries, J, et al. The 1982 revised criteria for classification of SLE. Arthritis Rheum 1982; 25: 1271-1272.
8. Weening, JJ, D'Agati, VD, Schwartz, MM, et al. International Society of Nephrology Working Group on the Classification of Lupus Nephritis, Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-530.
9. Font, J, Cervera, R, Ramos-Casals, M, et al. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum 2004; 33: 217-230.
10. Alarcon, GS, McGwin, G, Bertoli, AM, et al. for the LUMINA Study Group. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007; 66: 1168-1172.
11. Bosch, X, Guilabert, A, Pallares, L, et al. Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 2006; 15: 584-589.
12. Font, J, Ramos-Casals, M, Cervera, R, et al. Cardiovascular risk factors and the long-term outcome of lupus nephritis. QJM 2001; 94: 19-26.
13. Golbus, J, McCune, WJ. Lupus nephritis: classification, prognosis, immunopathogenesis and treatment. Rheum Dis Clin North Am 1994; 20: 213-241.
14. Rudnicki, RD, Gresham, GE, Rothfield, NF. The efficacy of antimalarials in systemic lupus erythematosus. J Rheumatol 1975; 2: 323-30.
15. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulphate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150-154.
16. Petri, M. Hydroxychloroquine prevents later damage in SLE. Arthritis Rheum 2001; 44: S280.
17. Costedoat-Chalumeau, N, Amoura, Z, Hulot, JS, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 3284-90.
18. Lafyatis, R, York, M, Marshak-Rothstein, A. Antimalarial agents: closing the gate on Toll-like receptors? Arthritis Rheum 2006; 54: 3068-3070.
19. Kasitanon, N, Fine, DM, Haas, M, Magder, LS, Petri, M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006; 15: 366-370.
20. Tsakonas, E, Joseph, L, Esdaile, JM, et al. The Canadian Hydroxychloroquine Study Group. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus 1998; 7: 80-85.
21. Barber, CE, Geldenhuys, L, Hanly, JG. Sustained remission of lupus nephritis. Lupus 2006; 15: 94-101.
22. Wallace, DJ. Antimalarials: the 'real' advance in lupus. Lupus 2001; 10: 385-387.
23. Andrade, RM, Alarcon, GS. Antimalarials in systemic lupus erythematosus: benefits beyond disease activity. Future Rheumatol 2006; 1: 225-233.
24. Bessant, R, Duncan, R, Ambler, G, et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. Arthritis Rheum 2006; 55: 892-899.
25. Wasko, MC, Hubert, HB, Lingala, VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007; 298: 187-193.
26. Tam, LS, Gladman, DD, Hallett, DC, Rahman, P, Urowitz, MB. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000; 27: 2142-2145.
27. Sachet, JC, Borba, EF, Bonfa, E, Vinagre, CG, Silva, VM, Maranhao, RC. Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 2007; 16: 273-278.
28. Calvo-Alen, J, McGwin, G, Toloza, S, et al. LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study. Ann Rheum Dis 2006; 65: 785-790.
29. Sotelo, J, Briceno, E, Lopez-Gonzalez, MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006; 144: 337-343.
30. Ruiz-Irastorza, G, Ugarte, A, Egurbide, MV, et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis 2007; 66: 815-817.
31. Nived, O, Jonsen, A, Bengtsson, AA, Bengtsson, C, Sturfelt, G. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol 2002; 29: 1398-1400.
32. Alarcón, GS, McGwin, G, Bastian, HM, et al. Systemic lupus erythematosus in three ethnic group VII: Predictors of early mortality in the LUMINA cohort. Arthritis Rheum 2001; 45: 191-202.
33. Urowitz, MB, Gladman, DD. Contribution of observational cohort studies in systemic lupus erythematosus: the University of Toronto Lupus Clinic experience. Rheum Dis Clin N Am 2005; 31: 211-221.
34. Molad, Y, Gorshtein, A, Wysenbeek, AJ, et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 2002; 11: 356-361.
35. Roman, MJ, Shanker, BA, Davis, A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-2406.